首页|磷酸西格列汀片仿制药药学研究的相关考虑

磷酸西格列汀片仿制药药学研究的相关考虑

扫码查看
磷酸西格列汀片为全球首个上市的二肽基肽酶-4(DPP-4)抑制剂,用于改善 2 型糖尿病患者的血糖控制,其仿制药的研发和注册申报成为近几年的一个热点。本文结合文献调研及近年审评经验,从处方开发、工艺研究、质量研究和控制、亚硝胺杂质控制、稳定性研究以及多规格间的BE试验豁免等方面,对磷酸西格列汀片仿制药药学研究中可能需要关注的问题进行探讨,以期为相关研发者提供一定的参考。
Relevant considerations on pharmaceutical research of Generic Sitagliptin Phosphate Tablets
Sitagliptin Phosphate Tablets was the first DPP-4 inhibitor that had been approved for the therapy of type 2 diabetes in the world,and the development and application of its generic drugs have become one of the hot spots in recent years.Based on literature investigation and recent review experience,this paper discusses some issues which may be considered during pharmaceutical research and development of Generic Sitagliptin Phosphate Tablets from the aspects of formulation design,manufacturing process development,quality research and control,nitrosamine impurities control,stability studies and additional strength biowaiver,etc.,in order to provide some references for researchers.

Sitagliptin phosphateGeneric drugsPharmaceutical researchNitrosamine impuritiesBiowaiver

吴小飞、刘丹杏、张歆、王宏亮

展开 >

国家药品监督管理局药品审评中心,北京 100076

磷酸西格列汀 仿制药 药学研究 亚硝胺杂质 生物等效性豁免

2024

药学研究
山东省药品检验所 山东省药学会

药学研究

CSTPCD
影响因子:0.653
ISSN:2095-5375
年,卷(期):2024.43(8)